Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.4350 (2.5%) ($10.4350 - $10.4350) on Mon. Mar. 22, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.93% (three month average) | RSI | 37 | Latest Price | $10.4350(2.5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.7% a day on average for past five trading days. | Weekly Trend | FOLD declines -1% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(57%) IWO(54%) IWM(51%) XBI(51%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -2.465% in a week (0% probabilities). VIXM(-30%) VXX(-14%) UUP(-12%) UNG(-6%) IGOV(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.465% (StdDev 4.93%) | Hourly BBV | 1.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-2.07(-119.84%) | Inflection Point | Yes | Resistance Level | $10.84 | 5 Day Moving Average | $10.36(0.72%) | 10 Day Moving Average | $10.48(-0.43%) | 20 Day Moving Average | $10.84(-3.74%) | To recent high | -58.1% | To recent low | 3.4% | Market Cap | $2.695b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |